The advanced role of carbon quantum dots in nanomedical applications

P Devi, S Saini, KH Kim - Biosensors and Bioelectronics, 2019 - Elsevier
Carbon quantum dots (CQDs) have emerged as a potential material in the diverse fields of
biomedical applications due to their numerous advantageous properties including …

Pharmacologic resistance in colorectal cancer: a review

WA Hammond, A Swaika… - Therapeutic advances in …, 2016 - journals.sagepub.com
Colorectal cancer (CRC) persists as one of the most prevalent and deadly tumor types in
both men and women worldwide. This is in spite of widespread, effective measures of …

[PDF][PDF] Management of brain metastases in tyrosine kinase inhibitor-naïve epidermal growth factor receptor-mutant non-small-cell lung cancer: a retrospective multi …

WJ Magnuson, NH Lester-Coll, AJ Wu… - J Clin …, 2017 - clf1.medpagetoday.com
Purpose Stereotactic radiosurgery (SRS), whole-brain radiotherapy (WBRT), and epidermal
growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are treatment options for …

[HTML][HTML] Probiotics: a promising candidate for management of colorectal cancer

A Tripathy, J Dash, S Kancharla, P Kolli, D Mahajan… - Cancers, 2021 - mdpi.com
Simple Summary Colorectal cancer being the third most frequently diagnosed cancer type,
is creating enormous physical, financial, and emotional burden on individuals as well as on …

[HTML][HTML] Brain tumor-targeted drug delivery strategies

X Wei, X Chen, M Ying, W Lu - Acta pharmaceutica sinica B, 2014 - Elsevier
Despite the application of aggressive surgery, radiotherapy and chemotherapy in clinics,
brain tumors are still a difficult health challenge due to their fast development and poor …

[HTML][HTML] EGFR-Based targeted therapy for colorectal cancer—Promises and challenges

B Janani, M Vijayakumar, K Priya, JH Kim… - Vaccines, 2022 - mdpi.com
Colorectal carcinoma (CRC) is the most lethal and common form of cancer in the world. It
was responsible for almost 881,000 cancer deaths in 2018. Approximately 25% of cases are …

EGFR signaling in colorectal carcinoma

AM Krasinskas - Pathology research international, 2011 - Wiley Online Library
The epidermal growth factor receptor (EGFR) and its downstream signaling pathways are
involved in the development and progression of several human tumors, including colorectal …

Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review

J Tol, CJA Punt - Clinical therapeutics, 2010 - Elsevier
Background: Two groups of agents targeting either the vascular endothelial growth factor
(VEGF) receptor or the epidermal growth factor receptor (EGFR) have been added to the …

[HTML][HTML] SK3/TRPC1/Orai1 complex regulates SOCE-dependent colon cancer cell migration: A novel opportunity to modulate anti-EGFR mAb action by the alkyl-lipid …

M Guéguinou, T Harnois, D Crottes, A Uguen… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Background Barely 10-20% of patients with metastatic colorectal cancer (mCRC) receive a
clinical benefit from the use of anti-EGFR monoclonal antibodies (mAbs). We hypothesized …

The blood-brain/tumor barriers: challenges and chances for malignant gliomas targeted drug delivery

C Zhan, W Lu - Current pharmaceutical biotechnology, 2012 - ingentaconnect.com
Treatment of malignant gliomas remains a challenge irrespective of the recent
improvements. Chemotherapeutic agents for malignant gliomas have been particularly …